Mounjaro is second obesity drug to be approved for use in England

Those with BMI of 35 and a comorbidity can now be prescribed tirzepatide and Nice says it is more effective than Wegovy

The medical treatment regulator for England has approved a second drug to combat obesity, giving patients and doctors what it says is a more effective alternative to semaglutide.

The National Institute for Health and Care Excellence (Nice) issued draft guidance on Tuesday recommending that very obese people should be prescribed tirzepatide, which is marketed in the UK as Mounjaro.